VULM 1457

an inhibitor of enzyme acyl-CoA: cholesterol acyltransferase (ACAT) seems to be a novel potential approach for a therapeutic treatment of dyslipidaemias and atherosclerosis

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Adameová, Adriana: 1 article (12/2007)
2.	Faberová, Viera: 1 article (12/2007)
3.	Kuzelová, Magdaléna: 1 article (12/2007)
4.	Ravingerová, Tána: 1 article (12/2007)
5.	Svec, Pavel: 1 article (12/2007)
6.	Adameová, A: 1 article (09/2006)
7.	Faberová, V: 1 article (09/2006)
8.	Kuzelová, M: 1 article (09/2006)
9.	Svec, P: 1 article (09/2006)

Related Diseases

1.	Reperfusion Injury 12/08/2007 - "Aside from remarkable hypolipidaemic activity, VULM 1457 improved the overall myocardial ischaemia-reperfusion injury outcomes in the diabetic-hypercholesterolaemic rats by suppressing arrhythmogenesis as well as by reducing myocardial necrosis." 09/01/2006 - "This study examined the effects of simvastatin (10 mg/ kg) and VULM 1457 (50 mg/kg), an ACAT inhibitor, in the heart model of 6 min ischemia followed by 10 min reperfusion injury in the diabetic-hypercholesterolaemic (DM-HCH) rats. " 12/08/2007 - "The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo." 12/08/2007 - "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet. "
2.	Necrosis 12/08/2007 - "Aside from remarkable hypolipidaemic activity, VULM 1457 improved the overall myocardial ischaemia-reperfusion injury outcomes in the diabetic-hypercholesterolaemic rats by suppressing arrhythmogenesis as well as by reducing myocardial necrosis."
3.	Ischemia 09/01/2006 - "This study examined the effects of simvastatin (10 mg/ kg) and VULM 1457 (50 mg/kg), an ACAT inhibitor, in the heart model of 6 min ischemia followed by 10 min reperfusion injury in the diabetic-hypercholesterolaemic (DM-HCH) rats. "
4.	Diabetes Mellitus 12/08/2007 - "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet. "
5.	Myocardial Infarction 12/08/2007 - "The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo."

Related Drugs and Biologics

1.	Simvastatin (Zocor)
2.	Streptozocin (Streptozotocin)
3.	Sterol O-Acyltransferase
4.	Cholesterol